Agenus to present three-year survival data from BOT+BAL Phase 1b study in MSS metastatic colorectal cancer at ESMO GI 2026

Agenus Inc.

Agenus Inc.

AGEN

0.00
  • Agenus flagged new three-year follow-up results from its Phase 1b C-800-01 BOT+BAL study in MSS metastatic colorectal cancer.
  • The updated survival and durability findings will be presented at ESMO GI 2026 in Munich on July 2, 2026.
  • The readout covers the fully enrolled 123-patient cohort without active liver metastases, extending prior two-year survival data shown at ESMO GI 2025.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agenus Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202606250700BIZWIRE_USPR_____20260625_BW863240) on June 25, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.